Rivals To Gain As Ranbaxy Loses Generic Nexium Exclusivity?
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy, the troubled Indian drug maker, has lost a big market exclusivity opportunity following the U.S. FDA’s approval of Teva’s application for generic Nexium. But Ranbaxy’s loss, apparently because of supply issues, may mean gains for some other manufacturers.